Page last updated: 2024-12-04

carbamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbamic acid is a simple organic compound with the formula H2NCOOH. It is a colorless solid that is unstable in the free state, readily decomposing to ammonia and carbon dioxide. However, its salts and esters, known as carbamates, are well-known and widely used. Carbamic acid itself is a key intermediate in the synthesis of urea, a major nitrogen-containing fertilizer and an important component of biological processes. Carbamic acid can be synthesized by reacting ammonia with carbon dioxide. It is also an important intermediate in the biosynthesis of pyrimidines, essential components of DNA and RNA. Carbamic acid's role in biological processes, its potential applications in agriculture, and its presence in various natural products make it an interesting subject of study.'

carbamic acid : A one-carbon compound that is ammonia in which one of the hydrogens is replaced by a carboxy group. Although carbamic acid derivatives are common, carbamic acid itself has never been synthesised. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID277
CHEMBL ID125278
CHEBI ID28616
MeSH IDM0192579

Synonyms (29)

Synonym
aminoameisensaeure
CHEBI:28616 ,
carbamidsaeure
463-77-4
C01563
aminoformic acid
carbamic acid
DB04261
NCGC00166327-01
azanium carbamate hydrate
CHEMBL125278
unii-o0uc6xos4h
o0uc6xos4h ,
AKOS006223007
bdbm50369454
aminomethanoic acid
FT-0689176
aminocarboxylic acid
KXDHJXZQYSOELW-UHFFFAOYSA-N
isocarbamic acid
imidocarbonic acid
iminocarbonic acid
formic acid, amino-
carbonimidic acid
DTXSID5048009
aminoformate
ammoniocarboxylate
Q412078
EN300-379173

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The administration of emetic agents in dogs for the purpose of gastric decontamination is not without risk, although the incidence of adverse effects is unknown and likely under-reported."( Side effects of powdered sodium carbonate (washing or 'Lectric' soda) used as an oral emetic agent in five dogs.
Indrawirawan, YH; Watson, AK, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
carbon oxoacid
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Nitrogen Metabolism2622
Uracil Degradation III616
Cyanate Degradation47
urea degradation I010
L-arginine degradation V (arginine deiminase pathway)012
cyanate degradation17
L-citrulline degradation110

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)67.00000.00000.933210.0000AID32277
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID32277Enzyme inhibitory activity towards Acetylcholinesterase1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Mixture-based synthetic combinatorial libraries.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (18.89)18.7374
1990's5 (5.56)18.2507
2000's24 (26.67)29.6817
2010's39 (43.33)24.3611
2020's5 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.13 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index83.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.13%)5.53%
Reviews6 (6.38%)6.00%
Case Studies3 (3.19%)4.05%
Observational0 (0.00%)0.25%
Other83 (88.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]